Opinion
Video
Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond
Author(s):
Saad Z. Usmani, MD, MBA, FACP, discusses noteworthy data presented at ASH 2024, including the IFM2017-03 trial, and shares his excitement for ongoing research efforts in multiple myeloma, emphasizing key areas where further investigation is needed to improve patient outcomes and refine treatment strategies.
Video content above is prompted by the following:
- Please discuss any other data in multiple myeloma released at ASH 2024 that you find noteworthy to share with colleagues.
- Outside of ASH 2024, what ongoing research efforts are you most excited for in the treatment of multiple myeloma, and what are some key areas where you think further research is needed to continue improving patient outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
December 26th 2024
